Sangamo Therapeutics (SGMO) Misses Q1 EPS by 71c, Miss on Revenues
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Price: $0.18 --0%
EPS Growth %: +25.0%
Financial Fact:
Total operating expenses: 22.03M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +25.0%
Financial Fact:
Total operating expenses: 22.03M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Sangamo Therapeutics (NASDAQ: SGMO) reported Q1 EPS of ($0.23), $0.71 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $12.64 million versus the consensus estimate of $53.09 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- C.H. Robinson acquires DeSpir Logistics for $75 million
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
